Loading
CACNA1G (Voltage-dependent T-type calcium channel subunit alpha-1G) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the 'low-voltage activated (LVA)' group and are strongly blocked by mibefradil.
Open Targets scores its association with cancer at 0.55 (direct and indirect evidence; datatypes literature 0.60, animal model 0.52, genetic association 0.00, clinical 0.87).
In plain words · CACNA1G (Voltage-dependent T-type calcium channel subunit alpha-1G) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
CACNA1G (Voltage-dependent T-type calcium channel subunit alpha-1G) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death.
No product in this corpus aims at CACNA1G yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CACNA1G: RNA tissue enhanced (brain 19 nTPM, cervix 8 nTPM, retina 8 nTPM); no normal tissue stained high; highest cancer staining head and neck cancer (2 of 4 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CACNA1G tissue; Open Targets ENSG00000006283 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Perez-Reyes et al, Nature, 1998, "Molecular characterization of a neuronal low-voltage-activated T-type calcium channel". Source.
Sources: HGNC HGNC:1394 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O43497 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000006283 (association with cancer (MONDO_0004992) 0.55; (GraphQL API, CC0))
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the 'low-voltage activated (LVA)' group and are strongly blocked by mibefradil. A particularity of this type of channel is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signalling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes. Location: Cell membrane; Cytoplasm (UniProt). Locus 17q21.33 (HGNC).
RNA: tissue enhanced (brain 19 nTPM, cervix 8 nTPM, retina 8 nTPM), detected in some normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Glioblastoma Multiforme 4 pTPM, Testicular Germ Cell Tumor 4 pTPM.
Medium only: cervical cancer, colorectal cancer, liver cancer, lung cancer.
HPA CACNA1G tissue · HPA CACNA1G pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CACNA1G" OR ABSTRACT:"CACNA1G" OR TITLE:"calcium voltage-gated channel subunit alpha1 G" OR ABSTRACT:"calcium voltage-gated channel subunit alpha1 G" OR TITLE:"Voltage-dependent T-type calcium channel subunit alpha-1G" OR ABSTRACT:"Voltage-dependent T-type calcium channel subunit alpha-1G" OR TITLE:"Cav3.1" OR ABSTRACT:"Cav3.1" OR TITLE:"NBR13" OR ABSTRACT:"NBR13") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CACNA1G, not a curated reading list.